An update on Alpers-Huttenlocher syndrome: pathophysiology of disease and rational treatment designs

References

• Harding BN Progressive neuronal degeneration of childhood with liver disease (Alpers-Huttenlocher Syndrome): a personal review. J Child Neurol. 1990;5:273–287.
   PubMed Web of Science ®Google Scholar
• Saneto RP, Cohen BH, Copeland WC, et al. Alpers-Huttenlocher syndrome. Pediatr Neurol. 2013;48(3):167–178.
   PubMed Web of Science ®Google Scholar
• Anagnostou ME, Ng YS, Taylor RW, et al. Epilepsy due to mutations in the mitochondrial polymerase gamma (POLG) gene: a clinical and molecular genetic review. Epilepsia. 2016;57(10):1531–1545.
   PubMed Web of Science ®Google Scholar
• Wolf NI, Rahman S, Schmitt B, et al. Status epilepticus in children with Alpers’ disease caused by POLG1 mutations: EEG and MRI features. Epilepsia. 2009;50(6):1596–1707.
   PubMed Web of Science ®Google Scholar
• Saneto RP, Lee IC, Koenig MK, et al. POLG testing as an emerging standard of care before instituting valproic acid for pediatric seizure disorders. Seizure. 2010;19(3):140–146.
   PubMed Web of Science ®Google Scholar
• Naviaux RK, Nyhan WL, Barshop BA, et al. Mitochondrial DNA polymerase γ deficiency and mtDNA depletion in a child with Alpers’ syndrome. Ann Neurol. 1999;45(1):54–58.
   PubMed Web of Science ®Google Scholar
• Horvath R, Hudson G, Ferrari G, et al. Phenotype spectrum associated with mutations of the mitochondrial polymerase γ gene. Brain. 2006;129(Pt 7):1674–1684
   PubMedGoogle Scholar
• deVries M Rodenburg RJ, Morava E, et al. Multiple oxidative phosphorylation deficiencies in severe childhood multi-system disorders due to polymerase gamma (POLG1) mutations. Eur J Pediatr. 2007;166(3):229–234.
   PubMedGoogle Scholar
• Tzoulis C, Engelsen BA, Telstad W, et al. The spectrum of clinical disease caused by the A457T and W748S POLG mutations: a study of 26 cases. Brain. 2006;129(Pt 7):1685–1692.
   PubMedGoogle Scholar
• Uusimaa J, Hinttala R, Rantala H, et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia. 2008;49(6):1038–1045.
   PubMed Web of Science ®Google Scholar
• Wiltshire E, Davidzon G, DiMauro S, et al. Juvenile Alpers disease. Arch Neurol. 2008;65(1):121–124.
   PubMedGoogle Scholar
• Harding BN, Alsanjari N, Smith SJ, et al. Progressive neurological degeneration of childhood with liver disease (Alpers’ disease) presenting in young adults. J Neurol Neurosurg Psychiatry. 1995;58(3):320–325.
   PubMed Web of Science ®Google Scholar
• Blackwood W, Buxton PH, Cumings JN, et al. Diffuse cerebral degeneration in infancy (Alper’s disease). Arch Dis Child. 1963;38:193–204.
   PubMed Web of Science ®Google Scholar
• Alpers BJ Diffuse progressive degeneration of the gray matter of the cerebrum. Arch Neurol Psychiatry. 1931;25:469–505.
   Google Scholar
• Morse WI Hereditary myoclonus epilepsy: two cases with pathological findings. Bull Johns Hopkins Hosp. 1949:84(2):116–133.
   PubMedGoogle Scholar
• Ford FR, Livingston S, Pryles CY Familial degeneration of the cerebral grey matter in childhood with convulsions, myoclonus, spasticity, cerebellar ataxia, choreo-athetosis, dementia, and death in status epilepticus; Differentiation of infantile and juvenile types. J Pediat. 1951; 39(1):33–43.
   PubMed Web of Science ®Google Scholar
• Huttenlocher PR, Solitare GB, Adams G Infantile diffuse cerebral degeneration with hepatic cirrhosis. Arch Neurol. 1976;33(3):186–192.
   PubMedGoogle Scholar
• Sandbank U, Lerman P Progressive cerebral poliodystrophy – Alpers’ disease. Disorganized Giant Neuronal Mitochondrial on Electron Microscopy. J Neurol Neurosurgery, and Psychiat. 1972;35(6):749–755.
   PubMed Web of Science ®Google Scholar
• Ropp PA, Copeland WC Cloning and characterization of the human mitochondrial DNA polymerase γ. Genomics. 1996;36(3):449–458.
   PubMed Web of Science ®Google Scholar
• Lecrenier N, Van Der Bruggen P, Fourty F Mitochondrial DNA polymerase from yeast to man: a new family of polymerases. Gene. 1997;185(1):147–152.
   PubMed Web of Science ®Google Scholar
• Naviaux RK, Nguyen KV POLG mutations associated with Alpers syndrome and mitochondrial DNA depletion. Ann Neurol. 2004;55(5):706–712.
   PubMed Web of Science ®Google Scholar
• cited on 2018 April 5] Available from: https://www.bing.com/images/search?view=detailV2&ccid=3bTs%2fFFH&id=BF5B4A8B4809A669E95C908052B03DE5CD56FCF9&thid=OIP.3bTs_FFH0e3JFLzxwfr4QwHaGc&mediaurl=https%3a%2f%2ftools.niehs.nih.gov%2fpolg%2f_assets%2fimages%2fPOLG_mutation.png&exph=3000&expw=3450&q=polg+mutation&simid=608022266264813628&selectedIndex=0&ajaxhist=0_https://tools.niehs.nih.gov/polg/_assets/documents/POLG-mutation-large_508.pdf_http://tools.niehs.nih.gov/polg/
   Google Scholar
• Stumpf JD, Saneto RP, Copeland WC Clinical and molecular features of POLG-related mitochondrial disease. Cold Spring Harb Perspect Biol. 2013;April 1;5(4):a011395.
   PubMed Web of Science ®Google Scholar
• Uusimaa J, Gowda V, McShane A, et al. Prospective study of POLG mutations in children with intractable epilepsy: prevalence and clinical features. Epilepsia. 2013;54(6):1002–1011.
   PubMed Web of Science ®Google Scholar
• Chan SS, Longley M, Copeland WC The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit. J Biol Chem. 2005;280(36):31341–31346.
   PubMed Web of Science ®Google Scholar
• Cerritelli SM, Frolova EG, Feng C, et al. Failure to produce mitochondrial DNA results in embryonic lethality in Rnasheh 1 null mice. Mol Cell. 2003;11(3):807–815.
   PubMed Web of Science ®Google Scholar
• Lee YS, Johnson KA, Molineux IJ, et al. A single mutation in human mitochondrial DNA polymerase PolgA affects both polymerization and proofreading activities of only the holoenzyme. J Biol Chem. 2010;285(36):28105–28116.
   PubMed Web of Science ®Google Scholar
• Lee YS, Kennedy WE, Yin YW Structural insight into processive human mitochondrial DNA synthesis and disease-related polymerase mutations. Cell. 2009;139(2):312–324.
   PubMed Web of Science ®Google Scholar
• Graziewicz MA, Longley MJ, Copeland WC DNA polymerase γ in mitochondrial DNA replication and repair. Chem Rev. 2006;106(2):383–405.
   PubMed Web of Science ®Google Scholar
• Ferrari G, Lamanea E, Donati A, et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-γA. Brain 2005;128(Pt 4):723–731.
   PubMedGoogle Scholar
• Saneto RP Genetics of mitochondrial disease. In: Advances in genetics. Volume 98. Elsevier Press 2017;98:63–116.
   Google Scholar
• Young MJ, Copeland WC Human mitochondrial DNA replication machinery and disease. Curr Opin Genet Dev. 2016;38:53–62.
   Web of Science ®Google Scholar
• Krasich R, Copeland WC DNA polymerases in the mitochondria: a critical review of the evidence. Front Biosci. 2017;22:692–709.
   Web of Science ®Google Scholar
• Young MJ Off-target effects of drugs that disrupt human mitochondrial DNA maintenance. Front Mol Biosci. 2017 Nov 22;4:74 doi: 10.3389/fmolb.2017.00074.
   Google Scholar
• Singh B, Li X, Owens KM, et al. Human REV3 DNA polymerase zeta localizes to mitochondria and protects the mitochondrial genome. PLoS One. 2015 Oct 13;10(10): e0140409.
   PubMed Web of Science ®Google Scholar
• Elo JM, Yadavalli SS, Euro L, et al. Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers. Hum Mol Genet. 2012:21(20):4521–4529.
   PubMed Web of Science ®Google Scholar
• Sofou K, Kollberg G, Holmstrom M, et al. Whole exome sequencing reveals mutations in NARS2 and PARS2, encoding the mitochondrial asparaginyl-tRNA synthetase and prolyl-tRNA synthetase, in patients with Alpers syndrome. Mol Genet Gen Med. 2015;3(1):59–68.
   PubMed Web of Science ®Google Scholar
• Hakonen AH, Isohanni P, Paetau A, et al. Recessive Twinkle mutations in early onset encephalopathy with mtDNA depletion. Brain. 2007;130(Pt 11):3032–3040.
   PubMedGoogle Scholar
• Sofou K, Moslemi A-R, Kollberg G, et al. Phenotypic and genotypic variability in Alpers syndrome. Eur J Paediatr Neurol. 2012;16(4):379–389.
   PubMed Web of Science ®Google Scholar
• Nguyen KV, Sharief FS, Chan SSL, et al. Molecular diagnosis of Alpers syndrome. J Hepatol. 2006;45(1):108–116.
   PubMed Web of Science ®Google Scholar
• Darin N, Oldfors A, Moslemi A-R, et al. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities. Ann Neurol. 2001;49:377–383.
   PubMed Web of Science ®Google Scholar
• Naviaux RK Alpers syndrome. Website: Orphanet: cited July 2006. Available from http://www.orpha.net/consor/cgi-bin/DiseaseSearch.php.Ing=EN&dataid=1730&Disease%28s%29/group%20of%20Alpers&Diseases=Alpers-syndrome-A;pers-Huttenlocher-syndrome-&title=Alpers-syndrome-Alpers-Huttenlocher-syndrome-&search=DiseaseSearchSimple.
   Google Scholar
• Euro L, Farnum GA, Palin E, et al. Clustering of Alpers disease mutations and catalytic defects in biochemical variants reveal new features of molecular mechanism of the human mitochondrial replicase, Pol γ. Nucl Acids Res 2011;39(21):9072–9084.
   PubMed Web of Science ®Google Scholar
• Wong L-JC, Brunetti-Pierra N, Zhang Q, et al. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat 2008 Sep;29(9):E150–172. .
   PubMedGoogle Scholar
• Saneto RP, Naviaux RK Polymerase gamma disease through the ages. Dev Disabil Res Rev. 2010;16(2):163–174.
   PubMed Web of Science ®Google Scholar
• West AP, Shadel GS, Ghosh S Mitochondria in innate immune responses. Nature Rev Immunol. 2011;11(6):389–402.
   PubMed Web of Science ®Google Scholar
• Lim SE, Ponamarev MV, Longley MJ, et al. Structural determinants in human DNA polymerase gamma account for mitochondrial toxicity from nucleoside analogs. J Mol Biol. 2003;329(1):45–57.
   PubMed Web of Science ®Google Scholar
• Bicknese AR, May W, Hickey WR, et al. Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity. Ann Neurol. 1992;32(6):767–775.
   PubMed Web of Science ®Google Scholar
• Hakonen AH, Heiskanen S, Juvonen V, et al. Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin. Am J Hum Genet. 2005;77(3):430–441.
   PubMed Web of Science ®Google Scholar
• Engelsen BA, Tzoulis C, Karlsen B, et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain. 2008;131(Pt 3):818–828.
   PubMedGoogle Scholar
• Chan SS, Longley MJ, Copeland WC Modulation of the W748S mutation in DNA polymerase gamma by the E1143G polymorphism in mitochondrial disorders. Hum Mol Genet. 2006;15(23):3473–3483.
   PubMed Web of Science ®Google Scholar
• Lee Y, Andaloussi S, Wood MIA Exosomes and microvesicles, extracellular vesicles for genetic information and gene therapy. Hum Mol Genet. 2012;21:R125–F134.
   PubMed Web of Science ®Google Scholar
• Alvarex-Erviti L, Soew Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotech. 2011;29:341–345.
   PubMed Web of Science ®Google Scholar
• Aminzadeh MA, Rogers RG, Fournier M, et al. Exosome-mediated benefits of cell therapy in mouse and human models of Duchene muscular dystrophy. Stem Cell Reports. 2018:10(3):942–955.
   PubMed Web of Science ®Google Scholar
• Safdar A, Bourgeois JM, Ogborn DI, et al. Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice.. Proc Natl Acad Sci USA. 2011;108(10):4135–4140.
   PubMed Web of Science ®Google Scholar
• Clark-Matott J, Saleem A, Dai Y, et al. Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain. Neurobiol Aging. 2015;36(11):2972–2983.
   PubMed Web of Science ®Google Scholar
• Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders (Review): Cochrane Database of System Rev. 2012 April 18 (4).CD004426. 10.1002/14651858.CD004426. pub3.
   PubMed Web of Science ®Google Scholar
• Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the mitochondrial medicine society. Genet Med. 2017;19. doi:10.1038/gim.2017.107. Epub 2017 Jul 2017.
   Google Scholar
• Rodriguez MC, MacDonald JR, Mahoney DJ, et al. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 2007;35(2):235–242.
   PubMed Web of Science ®Google Scholar
• Davidzon G, Mancuso M, Ferraris S, et al. POLG mutations and Alpers syndrome. Ann Neurol. 2005;57(6):921–923.
   PubMed Web of Science ®Google Scholar
• Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the mitochondrial medicine society. Genet Med. 2015:17(9):689–701.
   PubMed Web of Science ®Google Scholar
• Polyak E, Ostrovsky J, Peng M et al. N-acetylcysteine and vitamin E rescue animal longevity and cellular oxidative stress I pre-clinical models of mitochondrial complex I disease. Mol Genet and Metabol. 2018;123(4):449–462.
   PubMed Web of Science ®Google Scholar
• Khan NA, Nikkanen JU, Yatsuga S, et al. mTORC1 regulates mitochondrial integrated stress response and mitochondrial myopathy progression. Cell Metabol. 2017;26:419–428.
   PubMed Web of Science ®Google Scholar
• Nikkanen J, Forsstreom S, Euro L, et al., Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. Cell Metabol. 2016;23:635–648.
   PubMed Web of Science ®Google Scholar
• Siegmund SE, Yand H, Sharma R, et al. Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome. Hum Mol Genet. 2017;26:4588–4605.
   PubMed Web of Science ®Google Scholar
• Pitayu L, Baruffini E, Rodier C, et al. Combined use of Saccharomyces cerevisiae, Caenorhabditis elegans and patient fibroblasts leads to the identification of clofilium tosylate as a potential therapeutic chemical against POLG-related diseases. Hum Mol Genet. 2016;25:715–727.
   PubMed Web of Science ®Google Scholar
• Brat I, Hench J, Henriksson J, et al. Mitochondrial DNA level, which is provided by multiple mechanisms, and is not dependent on active replicase, is essential for Caenorhabiditis elegans development. Nucleic Acids Res. 2009;37:1817–1828.
   PubMed Web of Science ®Google Scholar
• Diener HC, Rahifs VW, Danesch U The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004;51(2):89–97.
   PubMed Web of Science ®Google Scholar
• Avula B, Wang Y, Wang M, et al. Simultaneous determination of sesquiterpenes and pyrrolizidine alkaloids rom the rhizomes of Petasites hydridus (L.) GM et Sch. and dietary supplements using UPLC-UV and HPLC-TOF-MS Methods J Pharm Biomed Anal. 2012;70:53–63.
   PubMed Web of Science ®Google Scholar
• Saneto RP Epilepsy and mitochondrial dysfunction: a single center’s experience. J Inborn Errors of Metab Screen. 2017;5:1–12.
   Google Scholar
• El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for treatment of MELAS Msyndrome. J Inborn Error Metab Screen. 2017 Jan;5. Doi:10.1177/2326409817697399. Epub 2017 Mar 24.
   PubMedGoogle Scholar
• El-Hattab AW, Adesina AM, Jones J, et al. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab 2015; 116 (1–2): 4–12.
   PubMed Web of Science ®Google Scholar
• Saneto RP, Friedman SD, Shaw DWW Neuroimaging of mitochondrial disease. Mitochondrion 2008; 8 (5–6): 396–413.
   PubMed Web of Science ®Google Scholar
• Tzoulis C, Tran GT, Coxhead J, et al. The molecular pathogenesis of POLG-γ related neurodegeneration. Ann Neurol. 2014;76(1):66–81.
   PubMed Web of Science ®Google Scholar
• Lax NZ, Grady J, Laude A, et al. Extensive respiratory chain defects in inhibitory interneuron in patients with mitochondrial disease. Neuropathol Appl Neurobiol. 2016:42(2):180–193.
   PubMed Web of Science ®Google Scholar
• Hikmat O, Tzoulis C, Chong WK, et al. The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. Genet Med 2017 Nov;19(11):1217–1225.
   PubMed Web of Science ®Google Scholar
• Lagrue E, Chalon S, Bodard S, et al. Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice. Pediatr Res. 2007;62(1):14019.
   Web of Science ®Google Scholar
• Ganetzky RD, Falk MJ 8-Year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease. Mol Genet Metab. 2018;123(3):301–308.
   PubMed Web of Science ®Google Scholar
• Naviaux RK Childhood Alpers-Huttenlocher syndrome. In: Saneto RP, Parikh S, Cohen BH, editors. Mitochondrial case studies: underlying mechanisms and diagnosis. Amsterdam: Elsevier; 2016: 135–148.
   Google Scholar
• Tang S, Wang J, Lee NC, et al. Mitochondrial DNA polymerase (gamma) mutations: an ever expanding molecular and clinical spectrum. J Med Genet. 2011;48(10):669–681.
   PubMed Web of Science ®Google Scholar
• Lee CF, Chavez JD, Garcia-Menendez L, et al. Normalization of NAD+ redox balance as a therapy for heart failure. Circulation. 2016;134(12):883–894.
   PubMed Web of Science ®Google Scholar
• Saneto RP Alpers-Huttenlocher syndrome: the role of a multidisciplinary health care team. J Mulitdisciplinary Heathcare. 2016;9:323–333.
   PubMed Web of Science ®Google Scholar
• Cohen BH, Chinnery PF, Copeland WC POLG-related disorders. In: Adam MP, Ardinger HH, Pagon RA, et al. eds. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2018. 2010 Mar 16 (updated 2018 Mar 1).
   Google Scholar
• Nikkanen J, Landoni JC, Balboa D, et al. A complex genomic locus drives mtDNA replicase POLG expression to its disease-related nervous system regions. EMBO Mol Med. 2018;10:13–21.
   PubMed Web of Science ®Google Scholar